BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 24324087)

  • 1. Wilms' Tumor Gene 1 (WT1)--loaded dendritic cell immunotherapy in patients with uterine tumors: a phase I/II clinical trial.
    Coosemans A; Vanderstraeten A; Tuyaerts S; Verschuere T; Moerman P; Berneman ZN; Vergote I; Amant F; VAN Gool SW
    Anticancer Res; 2013 Dec; 33(12):5495-500. PubMed ID: 24324087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunological response after WT1 mRNA-loaded dendritic cell immunotherapy in ovarian carcinoma and carcinosarcoma.
    Coosemans A; Vanderstraeten A; Tuyaerts S; Verschuere T; Moerman P; Berneman Z; Vergote I; Amant F; Van Gool SW
    Anticancer Res; 2013 Sep; 33(9):3855-9. PubMed ID: 24023319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunological response after therapeutic vaccination with WT1 mRNA-loaded dendritic cells in end-stage endometrial carcinoma.
    Coosemans A; Wölfl M; Berneman ZN; Van Tendeloo V; Vergote I; Amant F; Van Gool SW
    Anticancer Res; 2010 Sep; 30(9):3709-14. PubMed ID: 20944158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dendritic cell-based immunotherapy targeting Wilms' tumor 1 in patients with recurrent malignant glioma.
    Sakai K; Shimodaira S; Maejima S; Udagawa N; Sano K; Higuchi Y; Koya T; Ochiai T; Koide M; Uehara S; Nakamura M; Sugiyama H; Yonemitsu Y; Okamoto M; Hongo K
    J Neurosurg; 2015 Oct; 123(4):989-97. PubMed ID: 26252465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation and Cryopreservation of Clinical Grade Wilms' Tumor 1 mRNA-Loaded Dendritic Cell Vaccines for Cancer Immunotherapy.
    Smits EL; Stein B; Nijs G; Lion E; Van Tendeloo VF; Willemen Y; Anguille S; Berneman ZN
    Methods Mol Biol; 2016; 1393():27-35. PubMed ID: 27033213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy of autologous tumor lysate-loaded dendritic cell vaccines by a closed-flow electroporation system for solid tumors.
    Kamigaki T; Kaneko T; Naitoh K; Takahara M; Kondo T; Ibe H; Matsuda E; Maekawa R; Goto S
    Anticancer Res; 2013 Jul; 33(7):2971-6. PubMed ID: 23780988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant Wilms' tumour 1-specific dendritic cell immunotherapy complementing conventional therapy for paediatric patients with high-grade glioma and diffuse intrinsic pontine glioma: protocol of a monocentric phase I/II clinical trial in Belgium.
    Van Genechten T; De Laere M; Van den Bossche J; Stein B; De Rycke K; Deschepper C; Hazes K; Peeters R; Couttenye MM; Van De Walle K; Roelant E; Maes S; Vanden Bossche S; Dekeyzer S; Huizing M; Caluwaert K; Nijs G; Cools N; Verlooy J; Norga K; Verhulst S; Anguille S; Berneman Z; Lion E
    BMJ Open; 2024 Mar; 14(3):e077613. PubMed ID: 38503417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Immunotherapy for leukemia cells by using cytotoxic T lymphocyte specifically against WT1-derived peptide: an experimental study in vitro].
    Gu WY; Cao XS; Qiu GQ; Chen ZX; Sheng LX; Xie XB; He J; Cen JN; Shen HL
    Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(49):3475-80. PubMed ID: 16686063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting of the WT1
    Dagvadorj N; Deuretzbacher A; Weisenberger D; Baumeister E; Trebing J; Lang I; Köchel C; Kapp M; Kapp K; Beilhack A; Hünig T; Einsele H; Wajant H; Grigoleit GU
    Cancer Immunol Immunother; 2017 Mar; 66(3):319-332. PubMed ID: 27896368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.
    May RJ; Dao T; Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Zhang RH; Maslak P; Scheinberg DA
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4547-55. PubMed ID: 17671141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineering WT1-Encoding mRNA to Increase Translational Efficiency in Dendritic Cells.
    Benteyn D; Heirman C; Thielemans K; Bonehill A
    Methods Mol Biol; 2016; 1428():115-23. PubMed ID: 27236795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I/II trial of a WT1 (Wilms' tumor gene) peptide vaccine in patients with solid malignancy: safety assessment based on the phase I data.
    Morita S; Oka Y; Tsuboi A; Kawakami M; Maruno M; Izumoto S; Osaki T; Taguchi T; Ueda T; Myoui A; Nishida S; Shirakata T; Ohno S; Oji Y; Aozasa K; Hatazawa J; Udaka K; Yoshikawa H; Yoshimine T; Noguchi S; Kawase I; Nakatsuka S; Sugiyama H; Sakamoto J
    Jpn J Clin Oncol; 2006 Apr; 36(4):231-6. PubMed ID: 16611662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of dendritic cell vaccines pulsed with Wilms' tumour-1 peptide antigen on the survival of patients with advanced non-small cell lung cancers.
    Takahashi H; Okamoto M; Shimodaira S; Tsujitani S; Nagaya M; Ishidao T; Kishimoto J; Yonemitsu Y;
    Eur J Cancer; 2013 Mar; 49(4):852-9. PubMed ID: 23245331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Wilms' tumor gene 1 immunotherapy in pelvic gynecological malignancies.
    Coosemans A; Vergote I; Van Gool SW
    Expert Rev Clin Immunol; 2014 Jun; 10(6):705-11. PubMed ID: 24784346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. WT1 (Wilms' tumor gene 1): biology and cancer immunotherapy.
    Sugiyama H
    Jpn J Clin Oncol; 2010 May; 40(5):377-87. PubMed ID: 20395243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I/II clinical trial of a Wilms' tumor 1-targeted dendritic cell vaccination-based immunotherapy in patients with advanced cancer.
    Zhang W; Lu X; Cui P; Piao C; Xiao M; Liu X; Wang Y; Wu X; Liu J; Yang L
    Cancer Immunol Immunother; 2019 Jan; 68(1):121-130. PubMed ID: 30306202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase I dose-escalation clinical trial.
    Van Driessche A; Van de Velde AL; Nijs G; Braeckman T; Stein B; De Vries JM; Berneman ZN; Van Tendeloo VF
    Cytotherapy; 2009; 11(5):653-68. PubMed ID: 19530029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Wilms' Tumour gene 1 (WT1) as an immunotherapeutic target.
    Coosemans A
    Facts Views Vis Obgyn; 2011; 3(2):89-99. PubMed ID: 24753854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Grade Production of Wilms' Tumor-1 Loaded Cord Blood-Derived Dendritic Cells to Prevent Relapse in Pediatric AML After Cord Blood Transplantation.
    Plantinga M; Lo Presti V; de Haar CG; Dünnebach E; Madrigal A; Lindemans CA; Boelens JJ; Nierkens S
    Front Immunol; 2020; 11():559152. PubMed ID: 33101274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Wilms' tumor gene 1 (WT1) in endometrial carcinoma.
    Coosemans A; Moerman P; Verbist G; Maes W; Neven P; Vergote I; Van Gool SW; Amant F
    Gynecol Oncol; 2008 Dec; 111(3):502-8. PubMed ID: 18929401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.